COMPUMED MARKS MAY'S OSTEOPOROSIS AWARENESS AND PREVENTION MONTH BY TRANSFORMING HOW HEALTHCARE PROVIDERS SCREEN
COMPANY FOCUSES ON FAST-GROWING ASIAN MARKET, WHERE OSTEOPOROSIS IS ESPECIALLY PREVALENT; REMINDS ALL AT-RISK WOMEN TO GET TESTED

LOS ANGELES, May 22, 2006 -- CompuMed, Inc. (CMPD.OB) -- a leading developer of Computer Aided Diagnostic (CAD) solutions for the healthcare community -- is marking May's Osteoporosis Awareness and Prevention Month by working to transform how healthcare providers screen, diagnose and monitor the disease, which affects an estimated 200 million people worldwide (80 percent of whom are women). The disease poses an increased public health risk for Asian women, due mainly to the lack of calcium in the traditional Asian diet.

The company's novel, software-based OsteoGram(R) system provides a low-cost alternative to expensive, hardware-based systems that test for bone mineral density (BMD). It uses a hand x-ray derived from either digital or film-based x-ray equipment to perform quick and cost effective osteoporosis screening.

"We are well positioned to offer highly accurate and affordable testing for a disease that represents an extraordinary public healthcare need for millions of Asian women," said CompuMed CEO Jerry McLaughlin. "We encourage all at-risk women to get screened regularly for osteoporosis. Early detection can mean the difference between healthy bones and a series of progressively debilitating fractures."

To make the screening process more convenient, CompuMed is teaming up with Asian doctors and medical equipment manufacturers/distributors. The company recently helped sponsor the 1st Peripheral Densitometry Workshop (held in Hangzhou, China) and announced a new agreement with Kodak Electronic Products Shanghai Co., LTD to license and distribute the OsteoGram on medical imaging systems sold in the People's Republic of China.

In China alone, an estimated 90 million people suffer from osteoporosis. They incur more than 15 million fractures per year as a result of the disease. According to medical experts, 90 percent of Chinese citizens over age 60, and virtually all over age 70, have the disease. CompuMed's OsteoGram system is designed specifically to expand access to osteoporosis screening in such fast-growing markets.

Osteoporosis is a thinning of the bones that can lead to fractures, especially in older women. The disease poses a major public health threat for an estimated 44 million Americans, and costs the U.S. healthcare system in excess of $17 billion annually.

About CompuMed

Founded in 1973, CompuMed, Inc. (BB:CMPD) is a leading provider of computer-aided telemedicine and diagnostics technology. The Company's core products are the OsteoGram and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net or call (310) 258-5000.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning CompuMed's plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

CONTACT: Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.16, stellem@tellem.com